PMV Pharmaceuticals, Inc. (PMVP)
Stock Price:
$35.66 USD
0.36 (1.02%)
Updated Oct 21, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
1.53B |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-28.44M |
| Shares Out |
43.00M |
| EPS (ttm) |
-0.66 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 21, 2020 |
| Last Price |
$35.66 |
| Previous Close |
$35.30 |
| Change ($) |
0.36 |
| Change (%) |
1.02% |
| Day's Open |
35.35 |
| Day's Range |
34.44 - 36.45 |
| Day's Volume |
38,119 |
| 52-Week Range |
31.50 - 42.93 |
More Stats
| Market Cap |
1.53B |
| Enterprise Value |
1.45B |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
43.00M |
| Float |
28.82M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-0.66 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
186,922 |
| Short Ratio |
0.16 |
| Short % of Float |
0.65% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
10.47 |
| Revenue |
n/a |
| Operating Income |
n/a |
| Net Income |
-28.44M |
| Free Cash Flow |
n/a |
| Net Cash |
86.14M |
| Net Cash / Share |
2.00 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
n/a |
| ROE |
n/a |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
*No analysts have provided price targets for this stock.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | - | - |
| Operating Income | -26.64 | -18.89 |
| Net Income | -25.35 | -17.54 |
| Shares Outstanding | 3.04 | 3.01 |
| Earnings Per Share | -8.35 | -5.82 |
| Operating Cash Flow | -22.07 | -15.18 |
| Capital Expenditures | -0.11 | -0.45 |
| Free Cash Flow | -22.17 | -15.63 |
| Cash & Equivalents | 101 | 61.91 |
| Net Cash / Debt | 101 | 61.91 |
| Assets | 103 | 63.46 |
| Liabilities | 4.57 | 2.37 |
| Book Value | -70.47 | -46.14 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
PMV Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
38 |
| CEO |
David H. Mack |
Stock Information
| Ticker Symbol |
PMVP |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: PMVP |
| IPO Date |
September 25, 2020 |
Description
PMV Pharmaceuticals, a precision oncology company, discovery and development of small molecule, tumor-agnostic therapies for p53 mutations in cancer. Its lead product candidate is PC14586, a small molecule that corrects and restores p53 function. The company also develops product candidates for p53 R273H hotspot mutation and other p53 hotspot mutations. PMV Pharmaceuticals, Inc. was formerly known as PJ Pharmaceuticals, Inc. and changed to in July 2013. The company was founded in 2013 and is headquartered in Cranbury, New Jersey.